Neurological rehabilitation outcome of the treatment of patients with COVID-19 disease

Neurological rehabilitation outcome of the treatment of patients with COVID-19 disease - NRO-COV-50

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022845

Enrollment

500

Registered

2020-09-01

Start date

2020-06-19

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G62.80 G72.80

Interventions

Group 1: Patients with Covid-19 Group 2: Patients without Covid-19

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Age> = 18 years • COVID-19 pathogen detection using PCR (not for control group) • COVID-associated rehabilitation diagnosis (e.g. CIP / CIM, stroke, GBS, encephalopathy) For the non-COVID-19 CIP / CIM control group: Proven CIP / CIM as a qualifying NNFR diagnosis • Treatment from 1.1.2017 (i.b. for retrospective CIP / CIM control group) • Treatment in the NNFR for at least 48 hours • For a prospective sub-project: Written consent to study participation after detailed information

Exclusion criteria

Exclusion criteria: • For the prospective sub-project: Refusal to participate in the study • Pregnant or breastfeeding

Design outcomes

Primary

Measure	Time frame
In this multicentre combined retro- and prospective cohort study will be investigated (i.) How the clinical course of COVID-19 patients is in the NNFR, (ii.) How patients who suffered Covid-19 disease feel in medium and long term after being infected (3 and 6 months after being diagnosed) as well as how they recover from the disease (outcome) and (iii.) whether the clinical course and outcome of COVID-19 CIP / CIM patients differ from CIP / CIM patients of other etiologies without being infected with SARS-CoV-2. All 3 goals are equal primary study goals. For goal (i.) Characterization of the clinical course in the NNFR, the primary outcome measures are: Routine clinical scores on admission and discharge (modified Rankin scale [mRS], early rehabilitation Barthel index [FRBI], coma remission scale [KRS ] or Coma Recovery Scale - Revised [CRS-R], Mini-Mental-State-Exam [MMSE]) as well as the neurological examination findings. For goal (ii.), The primary outcomes are the global outcome, measured with mRS, health-related quality of life measured with EQ-5D, and independence in activities of daily living (ATL), measured with the FRBI. For goal (iii.), The outcomes from (i.) And (ii.) of the cohort of COVID-19-CIP / CIM patients are compared with those of a non-COVID-19-CIP / CIM control group.	—

Measure

Time frame

In this multicentre combined retro- and prospective cohort study will be investigated (i.) How the clinical course of COVID-19 patients is in the NNFR, (ii.) How patients who suffered Covid-19 disease feel in medium and long term after being infected (3 and 6 months after being diagnosed) as well as how they recover from the disease (outcome) and (iii.) whether the clinical course and outcome of COVID-19 CIP / CIM patients differ from CIP / CIM patients of other etiologies without being infected with SARS-CoV-2. All 3 goals are equal primary study goals. For goal (i.) Characterization of the clinical course in the NNFR, the primary outcome measures are: Routine clinical scores on admission and discharge (modified Rankin scale [mRS], early rehabilitation Barthel index [FRBI], coma remission scale [KRS ] or Coma Recovery Scale - Revised [CRS-R], Mini-Mental-State-Exam [MMSE]) as well as the neurological examination findings. For goal (ii.), The primary outcomes are the global outcome, measured with mRS, health-related quality of life measured with EQ-5D, and independence in activities of daily living (ATL), measured with the FRBI. For goal (iii.), The outcomes from (i.) And (ii.) of the cohort of COVID-19-CIP / CIM patients are compared with those of a non-COVID-19-CIP / CIM control group.

—

Secondary

Measure	Time frame
For goal (i.) Secondary outcomes are duration of treatment, duration of ventilation, occurrence of neurological and non-neurological complications, results of the routine EEG examination, results of the routine neurography examination, results of the routine CT / MRI examination. For goal (ii.) Secondary target variable, the assessment of personal performance and personal health status using a 10-point analogue scale compared the average of the last 7 days before the survey with the average status before the onset of COVID disease.	—

Measure

Time frame

For goal (i.) Secondary outcomes are duration of treatment, duration of ventilation, occurrence of neurological and non-neurological complications, results of the routine EEG examination, results of the routine neurography examination, results of the routine CT / MRI examination. For goal (ii.) Secondary target variable, the assessment of personal performance and personal health status using a 10-point analogue scale compared the average of the last 7 days before the survey with the average status before the onset of COVID disease.

—

Countries

Germany

Contacts

Public ContactGergana Drunin

FKI Ichenhausen

Gergana.Drunin@fachklinik-ichenhausen.de08223991034

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 6, 2026